MedTrace Logo

GARDASIL™ Vaccine Impact in Population Study (V501-033)

NCT01077856 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54516

Last updated 2022-09-13

Study results available
· View outcomes & findings →

Summary

This study will assess the impact of GARDASIL™ human papillomavirus (HPV) vaccine in the general female population by utilizing nationwide registry databases in the participating Nordic countries.

Conditions

  • Human Papillomavirus Infections

Sponsors & Collaborators

  • Danish Cancer Society

    collaborator OTHER

  • Union for International Cancer Control

    collaborator OTHER

  • Norwegian Institute of Public Health

    collaborator OTHER_GOV

  • Karolinska Institutet

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-29
Primary Completion
2014-12-02
Completion
2014-12-02

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01077856 on ClinicalTrials.gov